Literature DB >> 2912529

Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure).

J C Margetts1, U P Kalyan-Raman.   

Abstract

Giant-celled glioblastoma multiforme is characterized by bizarre multinucleated giant cells with abundant eosinophilic cytoplasm, paucity of vascular endothelial proliferation, and increased reticulin fibers. It is considered by Rubinstein to be a variant of glioblastoma multiforme and by Zülch to be of mesenchymal origin. We studied retrospectively ten cases of giant-celled glioblastoma to correlate clinical and pathological features including immunohistochemistry and ultrastructure, radiology and survival time. Seven men and three women ranging in age from 23-75 years had variable clinical presentations and well defined lesions on computed tomography (eight patients). Well-defined at surgery, the tumor was located in temporal (six patients), frontal (three patients), and parieto occipital (one patient) lobes. Besides characteristic histology, glial-fibrillary acidic protein was positive in all, along with intracytoplasmic fibrils on electron microscopy. Three patients died within 3 days of surgery. Of the surviving seven treated with radiation and/or chemotherapy, three had a survival time of more than 36 months and four less than 15 months. Our study identifies this tumor to be of astrocytic lineage, with temporal lobe predilection, and overall a longer survival rate than glioblastoma multiforme.

Entities:  

Mesh:

Year:  1989        PMID: 2912529     DOI: 10.1002/1097-0142(19890201)63:3<524::aid-cncr2820630321>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma.

Authors:  L Zipp; K M Schwartz; E Hewer; Y Yu; C Stippich; J M Slopis
Journal:  Clin Neuroradiol       Date:  2012-12       Impact factor: 3.649

2.  Successful treatment of a TSC2-mutant glioblastoma with everolimus.

Authors:  Andrew H Zureick; Kathryn A McFadden; Rajen Mody; Carl Koschmann
Journal:  BMJ Case Rep       Date:  2019-05-31

Review 3.  Pediatric giant cell glioblastoma: a case report and review of the literature.

Authors:  I De Prada; F Cordobés; D Azorín; T Contra; I Colmenero; I Glez-Mediero
Journal:  Childs Nerv Syst       Date:  2005-07-06       Impact factor: 1.475

4.  Giant cell glioblastoma multiforme: report of a case with prolonged survival and transformation to gliosarcoma.

Authors:  Prabal Deb; Mehar Chand Sharma; Bal Chander; Ashok Kumar Mahapatra; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2005-08-16       Impact factor: 1.475

5.  Clinicopathologic features of small cell glioblastomas.

Authors:  Hiroaki Takeuchi; Ryuhei Kitai; Tetsuya Hosoda; Shinsuke Yamada; Norichika Hashimoto; Ken-ichiro Kikuta; Yukio Shimizu; Hirohiko Kimura
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

6.  A histopathological contribution to supratentorial glioma grading, definition of mixed gliomas and recognition of low grade glioma with Rosenthal fibers.

Authors:  J M Cillekens; J A Beliën; P van der Valk; T J Faes; P J van Diest; M A Broeckaert; J H Kralendonk; W Kamphorst
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 7.  The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.

Authors:  Swati Mahajan; Iman Dandapath; Ajay Garg; Mehar C Sharma; Vaishali Suri; Chitra Sarkar
Journal:  Lab Invest       Date:  2022-01-14       Impact factor: 5.662

8.  Pediatric giant cell glioblastoma: New insights into a rare tumor entity.

Authors:  Michael Karremann; Sandra Butenhoff; Ulrike Rausche; Torsten Pietsch; Johannes E A Wolff; Christof M Kramm
Journal:  Neuro Oncol       Date:  2008-12-02       Impact factor: 12.300

9.  Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.

Authors:  Kevin R Kozak; John S Moody
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

10.  Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Authors:  J A B van Genugten; P Leffers; B G Baumert; H Tjon-A-Fat; A Twijnstra
Journal:  J Neurooncol       Date:  2009-07-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.